Nörolojik ve Psikiyatrik Bozukluklarda Sodyum Butiratın Terapötik Potansiyeli.
Therapeutic Potential of Sodium Butyrate in Neurological and Psychiatric Disorders.
DOI: 10.1007/s12035-025-05428-wPMID: 41261258
Therapeutic Potential of Sodium Butyrate in Neurological and Psychiatric Disorders.
DOI: 10.1007/s12035-025-05428-wPMID: 41261258
Nrf2-Keap1 Pathway and NLRP3 Inflammasome in Parkinson's Disease: Mechanistic Crosstalk and Therapeutic Implications.
DOI: 10.1007/s12035-025-05389-0PMID: 41261343
Exploring the Pharmaceutical Significance and Analytical Landscape of Ropinirole: An In-Depth Review of an Indole-Based Dopaminergic Therapeutic Agent.
DOI: 10.1080/10408347.2025.2586047PMID: 41267559
A Red-Emitting Fluorescent Probe for Visualizing Hydroxyl Radical in Parkinson's Disease and Guiding the Discovery of Methyl Ferulate for Therapeutic Intervention.
DOI: 10.1021/acs.analchem.5c04954PMID: 41264672
Pathological microtubule dynamics in Parkinson's disease: Mechanisms and therapeutic implications.
DOI: 10.1016/bs.apcsb.2025.10.019PMID: 41904012
Voltammetric analysis of entacapone, levodopa, and carbidopa in tablets: A chemometric approach.
DOI: 10.1016/j.jpba.2025.117275PMID: 41273958
Are there gender differences in adverse drug reactions to levodopa? A real-world safety comparison in the global pharmacovigilance database.
DOI: 10.1016/j.therap.2025.11.004PMID: 41372028
Circadian Rhythm Dysfunction in Neurodegenerative Diseases: A Bidirectional Perspective and Therapeutic Potential.
DOI: 10.2147/nss.s561326PMID: 41287625
Levodopa/carbidopa/entacapone versus levodopa/benserazide plus pramipexole in Chinese patients with Parkinson's disease experiencing wearing off.
DOI: 10.3389/fneur.2025.1682614PMID: 41346381
Opicapone for the Treatment of Nocturnal Hypokinesia in Patients With Parkinson's Disease: An Open-Label Pilot Clinical Trial.
DOI: 10.14802/jmd.25250PMID: 41261362
Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Extended Real World Data with Outpatient Dose Titration.
DOI: 10.1002/mdc3.70397PMID: 41257419
REPLY: Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Extended Real World Data With Outpatient Dose Titration.
DOI: 10.1002/mdc3.70396PMID: 41257466
Kayıtlar bilimsel kaynaklardan alınır. Bibliyografik kayıt sayısı, Türkçe çeviri veya editoryal onay sayısı değildir.